Long-term safety of zomepirac: a double-blind comparison with aspirin in patients with osteoarthritis.
Zomepirac at daily doses of 400 to 600 mg was well tolerated and provided continuing effective analgesia in the relief of chronic pain associated with osteoarthritis. In this long-term safety study, patients treated with zomepirac had significantly fewer adverse reactions and fewer limiting adverse reactions than did patients treated with aspirin. Thus zomepirac, which has previously shown efficacy in single-dose studies as well as good patient acceptability and efficacy in circumstances typical of clinical practice, has been found in this study to compare favorably to aspirin in a long-term (12-week) study in 238 patients with chronic pain secondary to osteoarthritis.
D000700:Analgesics / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D001241:Aspirin / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010003:Osteoarthritis / Q000188:drug therapy*; D011758:Pyrroles / Q000009:adverse effects*; D014046:Tolmetin / Q000009:adverse effects* / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use
D000700:Analgesics; D011758:Pyrroles; C020549:zomepirac; D014046:Tolmetin; D001241:Aspirin